Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Short term Debt (2019 - 2022)

BioScience Health Innovations (BHIC) has disclosed Short term Debt for 4 consecutive years, with $2893.0 as the latest value for Q2 2022.

  • Quarterly Short term Debt fell 64.94% to $2893.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $2893.0 through May 2022, down 64.94% year-over-year, with the annual reading at $8713.0 for FY2021, 1046.45% up from the prior year.
  • Short term Debt for Q2 2022 was $2893.0 at BioScience Health Innovations, roughly flat from $2893.0 in the prior quarter.
  • The five-year high for Short term Debt was $8713.0 in Q3 2021, with the low at $760.0 in Q3 2020.
  • Average Short term Debt over 4 years is $5385.1, with a median of $6215.0 recorded in 2020.
  • The sharpest move saw Short term Debt soared 1046.45% in 2021, then crashed 64.94% in 2022.
  • Over 4 years, Short term Debt stood at $6115.0 in 2019, then rose by 15.31% to $7051.0 in 2020, then tumbled by 58.97% to $2893.0 in 2021, then changed by 0.0% to $2893.0 in 2022.
  • According to Business Quant data, Short term Debt over the past three periods came in at $2893.0, $2893.0, and $2893.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.